QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 bolt-biotherapeutics-q2-eps-446-beats-627-estimate-sales-180m-beat-81975k-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(4.46) per share which beat the analyst consensus estimate of ...

 bolt-biotherapeutics-to-effect-1-for-20-reverse-stock-split

-SEC Filing

 lake-street-initiates-coverage-on-bolt-biotherapeutics-with-buy-rating-announces-price-target-of-4

Lake Street analyst Chad Messer initiates coverage on Bolt Biotherapeutics (NASDAQ:BOLT) with a Buy rating and announces Pri...

 stifel-maintains-hold-on-bolt-biotherapeutics-lowers-price-target-to-1

Stifel analyst Stephen Willey maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Hold and lowers the price target from $1.2...

 bolt-biotherapeutics-q1-eps-029-beats-036-estimate-sales-122m-beat-76750k-estimate

Bolt Biotherapeutics (NASDAQ:BOLT) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of ...

 bolt-biotherapeutics-announces-it-will-host-key-opinion-leader-conference-call-and-webcast-to-discuss-bdc-3042-phase-1-results-monday-may-12-2025-at-230-pm-pt--530-pm-et

Conference call and webcast on Monday, May 12, 2025, at 2:30 p.m. PT / 5:30 p.m. ET- Bolt Biotherapeutics (NASDAQ:BOLT), a biop...

 bolt-biotherapeutics-presents-preclinical-results-from-next-generation-boltbody-isacs-targeting-ceacam5-and-pd-l1-at-aacr-annual-meeting

CEA-targeted ISAC elicits complete responses in mice and is well-tolerated in NHPsPD-L1 ISAC directly activates and reprograms ...

 hc-wainwright--co-reiterates-neutral-on-bolt-biotherapeuticsto-neutral

HC Wainwright & Co. analyst Edward White reiterates Bolt Biotherapeutics (NASDAQ:BOLT) from Neutral to Neutral.

 stifel-maintains-hold-on-bolt-biotherapeutics-lowers-price-target-to-125

Stifel analyst Stephen Willey maintains Bolt Biotherapeutics (NASDAQ:BOLT) with a Hold and lowers the price target from $1.5...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION